Citalopram 40mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Citalopram hydrobromide

Available from:

Rivopharm (UK) Ltd

ATC code:

N06AB04

INN (International Name):

Citalopram hydrobromide

Dosage:

40mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 04030300; GTIN: 5060388650261

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER
CITALOPRAM 10MG, 20MG & 40MG TABLETS
Citalopram hydrobromide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU
•
Citalopram Tablets treat depression and anxiety disorders but they
will not work straight away. Like all medicines, it can have
side-effects.
It is important that you and your doctor talk about the benefits and
the possible unwanted effects of the medicine before you start taking
it.
•
Citalopram Tablets must be taken with care by children
or teenagers under 18. (See Section 2 on page 3).
•
Citalopram Tablets will not work straight away. You may feel worse
before feeling better after starting the medicine. Your doctor should
ask to see you again 2 or 3 weeks after you first start taking the
medicine. Tell your doctor if you feel no better.
(See Section 3 on page 5).
•
Some people with depression or anxiety think of harming or killing
themselves. If you have any of these thoughts, see your doctor or
go to a hospital straight away. (See Section 2 on page2).
•
If you feel restless or feel like you cannot keep still, go to your
doctor. If you keep on taking more Citalopram Tablets each day,
it may make these feelings worse. (See Section 4 on page 6).
•
Talk to your doctor before you stop taking Citalopram Tablets.
If you stop taking it suddenly or miss a dose you may get unwanted
effects. (See Section 4 on page 6).
•
Taking some other medicines with Citalopram Tablets can cause
problems. You may need to talk to your doctor first. (See Section 2 on
page 2).
•
If you are pregnant or planning to get pregnant, talk to your doctor
before taking Citalopram Tablets.
(See Section 2 on page 2).
Keep this leaflet. You may need to read it again. If you have further
questions, please ask your doctor or pharmacist or nurse.
This medicine has been prescribed for you. Do not pass it to others.
It may harm them, even if their sign of illness are the same as yours.
If you get any of the side ef

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Citalopram 40mg Tablets.
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each
film-coated
tablet
contains
49.96mg
of
Citalopram
hydrobromide
equivalent to 40mg of Citalopram.
For full list of excipients, see 6.1
3
PHARMACEUTICAL FORM
Film coated tablets.
Oval, biconvex, white colour, film coated tablets, scored on one side
and with
marking 40 on the other side.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For treatment of depressive illness in the initial phase and as
maintenance
against potential relapse/recurrence.
Citalopram is also indicated in the treatment of panic disorder with
or without
agoraphobia.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Depression
Adults:
Citalopram should be administered as a single oral dose of 20 mg
daily.
Dependent on individual patient response, the dose may be increased to
a
maximum of 40 mg daily. _ _
In general improvement in patients starts after one week but may only
become
evident from the second week of therapy.
As with all antidepressant medicinal products, dosage should be
reviewed and
adjusted if necessary within 3 to 4 weeks of initiation of therapy and
thereafter
as judged clinically appropriate. Dosage adjustments should be made
carefully
on an individual patient basis, to maintain the patient at the lowest
effective
dose.
Patients with depression should be treated for a sufficient period of
at least 6
months to ensure that they are free from symptoms.
PANIC DISORDER
Adults:
A single oral dose of 10 mg is recommended for the first week before
increasing the dose to 20 mg daily. Dependent on individual patient
response,
the dose may be increased to a maximum of 40 mg daily.
A
low
initial
starting
dose
is
recommended
to
minimise
the
potential
worsening of panic symptoms, which is generally recognised to occur
early in
the treatment of this disorder. Dosage adjustments should be made
carefully
on an individual patient basis, to maintain the patients at the lowest
effective
dose.
_ _
Patients with panic